WHAT IS CLAIMED IS:

1. ~~A method of treating a metabolic disease or condition in an individual, comprising administering to the individual an effective amount~~ Use of an anti-fibroblast growth factor receptor-1 (FGFR1) agonist in the manufacture of a medicament for treating a metabolic disease or condition in an individual, wherein the metabolic disease is selected from the group consisting of: polycystic ovary syndrome (PCOS), metabolic syndrome (MetS), obesity, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), hyperlipidemia, hypertension, type 2 diabetes, non-type 2 diabetes, type 1 diabetes, latent autoimmune diabetes (LAD), and maturity onset diabetes ~~fo~~ of the young (MODY), wherein the FGFR1 agonist does not activate FGFR2 or FGFR3.

2. The ~~method~~ use of claim 1, wherein the FGFR1 agonist is an anti-FGFR1 antibody.

3. The use ~~method~~ of claim 2, wherein the anti-FGFR1 antibody binds to peptide #26 KLHAVPAAKTVKFKCP (SEQ ID NO: 28) or peptide #28 FKPDHRIGGYKVRY (SEQ ID NO: 29).

4. The use ~~method~~ of claim 2, wherein the anti-FGFR1 antibody binds to both FGFR1b and FGFR1c.

5. The use ~~method~~ of any one of claims ~~1~~2-4, wherein the antibody is a bispecific antibody.

6. The use ~~method~~ of claim 5, wherein the antibody also binds to beta-Klotho.

7. An isolated antibody that binds to FGFR1, wherein the antibody is an agonist of FGFR1 activity.

8. The isolated antibody of claim 7, wherein the antibody is not an agonist of FGFR2 or FGFR3.

9. The antibody of claim 7 or 8, wherein the antibody is a monoclonal antibody.

33. The use of claim 31, wherein the medicament is for sensitizing an individual to insulin.

34. ~~A method of treating diabetes in an individual, comprising administering to the individual an effective amount~~ Use of the antibody according to any one of claims 7-22 in the manufacture of a medicament for treating diabetes in an individual.

35. The ~~method~~ use of claim 34, wherein the medicament is to be administered with ~~further comprising administering to the individual~~ another agent to treat diabetes provided that the other agent is not insulin.

36. The ~~method~~ use of claim 34, wherein the medicament is to be administered with ~~further comprising administering to the individual~~ an agent to treat cardiovascular disease.